Clinical Trials
16
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
- Conditions
- Peripheral Arterial Diseases
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Angiodynamics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06777901
- Locations
- 🇺🇸
CIS Grey ASC, Gray, Louisiana, United States
Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
- Conditions
- Acute Pulmonary Embolism (PE)Pulmonary Embolism
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Angiodynamics, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT06697314
Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
- Conditions
- Pulmonary EmbolismAcute Pulmonary Embolism
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Angiodynamics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT05318092
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸UCLA Health, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
- Conditions
- Prostate Cancer
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Angiodynamics, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT04972097
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of Florida Health, Gainesville, Florida, United States
Post-Market Registry of AURYON™ Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
- Conditions
- Infrainguinal Peripheral Artery DiseasePADPeripheral Arterial Disease
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Angiodynamics, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04229563
- Locations
- 🇺🇸
Pulse Cardiovacular, Scottsdale, Arizona, United States
🇺🇸Pima Vascular, Tucson, Arizona, United States
🇺🇸Comprehensive Cardiovascular, Davenport, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
AngioDynamics Initiates RECOVER-AV Trial for Pulmonary Embolism Treatment Device
AngioDynamics has enrolled the first patient in the RECOVER-AV clinical trial, evaluating the AlphaVac F1885 System for treating intermediate-risk pulmonary embolism across multiple international sites.
AngioDynamics Launches AMBITION BTK Trial to Evaluate Auryon Laser System for Critical Limb Ischemia
AngioDynamics initiates the AMBITION BTK randomized controlled trial and registry to assess the Auryon laser atherectomy system's effectiveness in treating below-the-knee lesions in critical limb ischemia patients.
AngioDynamics' NanoKnife System Receives FDA Clearance for Prostate Tissue Ablation
AngioDynamics has received FDA clearance for its NanoKnife System for prostate tissue ablation, marking a significant advancement in minimally invasive cancer treatment.
AngioDynamics Launches Long-Term Study of NanoKnife for Prostate Cancer Treatment
AngioDynamics and UCLH have initiated a prospective registry study to assess the long-term efficacy and safety of the NanoKnife system in treating intermediate-risk prostate cancer.
AngioDynamics Launches RECOVER-AV Trial for AlphaVac System in Pulmonary Embolism Treatment
AngioDynamics has initiated the RECOVER-AV trial to assess the AlphaVac F1885 System's safety and efficacy in treating acute, intermediate-risk pulmonary embolism (PE).